GSK Exercises Option for Ionis’ Hepatitis B Programmes
By Michelle Liu
Pharma Deals Review: Vol 2019 Issue 9 (Table of Contents)
Published: 3 Sep-2019
DOI: 10.3833/pdr.v2019.i9.2453 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
As it faces generic competition for its respiratory blockbuster Advair (fluticasone propionate/salmeterol), GlaxoSmithKline (GSK) has looked to Ionis Pharmaceuticals for its next revenue source by exercising its option to license two of its antisense therapies, IONIS-HBVRx and IONIS-HBV-LRx, for the treatment of chronic hepatitis B virus infection...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS